Zocor Can Increase Chance Of Muscle Injury & Kidney Damage: FDA

Zocor Can Increase Chance Of Muscle Injury & Kidney Damage: FDA

While myopathy (muscle injury) is a known side effect for all cholesterol-lowering statin medications, the FDA has just issued a warning that, when prescribed and used at higher doses, Zocor (generic name: simvastatin) carries with it a greater risk of developing muscle injury, including the most serious form of myopathy, rhabdomyolysis, which can lead to kidney damage, kidney failure, and possibly death. [More]

Pfizer Launches Campaign To Warn Users Away From Generic Competitor

Pfizer Launches Campaign To Warn Users Away From Generic Competitor

Pfizer is in panic mode about its rapid decline in Lipitor sales—in the last 18 months, it has dropped from 40% of the market for cholesterol-lowering drugs to 30%, and likely to drop further—so it’s launched a big media-blitz to convince people not to switch to simvastatin, the generic version of its name-brand competitor, Zocor. Zocor was more expensive than Lipitor, so Pfizer had nothing to worry about for years—but then Zocor lost its patent protection last year, and now doctors are switching patients from Lipitor over to Zocor’s generic twin to save money.